MSB 2.01% $1.52 mesoblast limited

MSB Trading - 2019, page-1947

  1. 205 Posts.
    lightbulb Created with Sketch. 105
    The full article for the LVAD trial was published in JAMA in March for anyone who interested and has access. I’ve had a good read through it and there is no change in any outcome except GI bleeding including echo parameters such as LVEF, RV function, LVEDV or LVESV.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.